Analysts had plenty of questions but Esperion Therapeutics Inc. offered few answers regarding the FDA's stalling on oral, once-daily bempedoic acid (ETC-1002) for lipid lowering, after the agency told company officials it's uncertain about an acceptable endpoint and how the treatment paradigm might transform.